MV-ZIKA

ZIKAVAX

at a glance

TARGET DISEASE

Zika virus Disease

TIMELINE

01 October 2016 to 30 September 2020

COORDINATOR

European Vaccine Initiative

FUNDER

European Union

FUNDING

4.9 Mio Euro

SUMMARY

Fast track development of a Zika vaccine based on measles vector

The ZIKAVAX project aims at developing a safe, effective, and affordable preventive vaccine against Zika virus infection. To achieve this goal, ZIKAVAX uses a delivery platform technology based on a measles vector (MV) with demonstrated proof of principle in humans and a preclinical track record of rapid adaptability and effectiveness for a variety of pathogens. In ZIKAVAX, following antigen selection and expression, immunisation studies were conducted with the Zika vaccine candidate in mice and in a non-human primates challenge model that was developed by the consortium. The ultimate goal of ZIKAVAX is the demonstration of safety and immunogenicity of a recombinant measles-Zika vaccine candidate (MV-ZIKA) in adult volunteers in a phase Ia clinical trial.

PARTNERS

Commissariat à l’énergie atomique et aux énergies alternatives (CEA) (France); European Vaccine Initiative (EVI) (Germany); Institut Pasteur (France); Themis Bioscience (Austria).

Partners List

Join European Vaccine Initiative mailing list for updates on projects, training and funding opportunities

© 2020 European Vaccine Initiative. Designed by European Vaccine Initiative